Claims for Patent: 5,834,200

Summary for Patent: 5,834,200

Title:	Marker at the estrogen receptor gene for determination of osteoporosis predisposition
Abstract:	The present invention relates to a method of determining predisposition to low or high bone mineral density and to development of osteoporosis of a patient, which comprises determining estrogen receptor polymorphism in linkage disequilibrium in a biological sample of said patient, wherein heterozygosity is associated with high bone density and homozygosity is associated with low bone density.
Inventor(s):	Rousseau; Fran.cedilla.ois (Ste-Foy, CA)
Assignee:	Universite Laval, Cite Universitaire (Quebec, CA)
Application Number:	08/892,248
Patent Claims:	1. A method of determining predisposition to low or high bone density of a human patient, which comprises determining estrogen receptor polymorphism in linkage disequilibrium in a biological sample of said human patient, wherein heterozygosity is associated with high bone density and homozygosity is associated with low bone density, said estrogen receptor polymorphism being selected from the ground consisting of a PvuII polymorphic site located in the first intron of the estrogen receptor gene and a DNA variant or mutation which shows linkage disequilibrium with one of the alleles of the PvuII polymorphism located in the first intron of the estrogen receptor gene. 2. The method of claim 1, wherein detecting said estrogen receptor polymorphism comprises analysis of a restriction fragment length polymorphism using endonuclease digestion. 3. The method of claim 2, which further comprises a step prior to said estrogen receptor gene digestion, wherein at least a fragment of said estrogen receptor is amplified. 4. The method of claim 1, wherein said polymorphism of the estrogen receptor gene is detected using at least one oligonucleotide specific to the normal or variant estrogen receptor gene allele. 5. The method of claim 3, wherein said fragment of said estrogen receptor is amplified by polymerase chain reaction. 6. The method of claim 1, wherein low bone density is predisposition to osteoporosis and/or bone fracture of said patient during post-menopause. 7. The method of claim 1, wherein high bone density is indicative of resistance to osteoporosis and/or bone fracture of said patient during post-menopause. 8. The method of claim 1, wherein estrogen receptor genotyping is indicative of response to therapy and/or to preventive treatments against low bone mineral density and bone and vertebrae fractures. 9. A prognosis kit for determining predisposition to low or high bone mineral density of a human patient, which comprises at least a probe specific for estrogen receptor wherein said probe is capable of detecting an estrogen receptor polymorphism, said estrogen receptor polymorphism being selected from the group consisting of a PvuII polymorphic site located in the first intron of the estrogen receptor gene and a DNA variant or mutation which shows linkage disequilibrium with one of the alleles of the PvuII polymorphism located in the first intron of the estrogen receptor gene. 10. The method of claim 1, where said linkage disequilibrium is statistically significant by the Chi square test. 11. The method of claim 1, wherein said estrogen receptor polymorphism is the PvuII polymorphism. 12. The kit of claim 9, wherein said kit further comprises instructions for the diagnosis of a predisposition to low or high bone density.

Details for Patent 5,834,200

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132	06/04/1986		2016-01-25
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132			2016-01-25
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	Injection	103132			2016-01-25